See Bull Run's current pages for Divi's Laboratories and Syngene International. For another CDMO comparison, see Bull Run's Divi's Laboratories vs Laurus Labs analysis.

Q1 FY27 scorecard: the operating gap was enormous

Why the businesses are not directly comparable

Divi's primarily earns money when a physical pharmaceutical ingredient or intermediate is manufactured and supplied.

Syngene can earn money much earlier in the drug-development cycle.

A customer can hire Syngene for:

• medicinal chemistry;
• biology;
• drug metabolism and pharmacokinetics;
• toxicology;
• translational science;
• analytical development;
• formulation development;
• clinical research support;
• API manufacturing;
• biologics manufacturing.

This gives Syngene a much broader addressable market.

Syngene's main business is still Research Services

That is critical to understanding the stock.

Syngene is often described alongside pure pharmaceutical CDMOs.

But most current revenue still comes from scientific services rather than commercial manufacturing.

Research economics are heavily influenced by scientific headcount and laboratory utilisation.

Research Services can be attractive when laboratories are full

Much of Syngene's work can be billed through:

• full-time-equivalent arrangements;
• fee-for-service contracts;
• dedicated research centres;
• project milestones;
• outcome-based models.

When scientific teams and laboratories are highly utilised, incremental revenue can produce good margins.

When work disappears, employee costs remain.

That creates operating leverage in both directions.

Q1 showed the downside of that fixed-cost structure

Revenue declined 16%.

Operating EBITDA declined 56%.

Operating margin fell from approximately 24% to around 12%.

This is severe negative operating leverage.

The revenue loss was not large enough to explain the profit collapse by itself.

The fixed-cost structure magnified it.

One major biologics customer was central to the decline

Syngene had previously manufactured biologics associated with animal-health products for this customer.

When the customer reduced or paused offtake, Syngene's installed manufacturing capacity could not immediately be filled with another commercial product.

This is a classic CDMO concentration risk.

A commercial biologics customer cannot be replaced overnight

Biologic manufacturing requires:

• cell-line and process transfer;
• engineering batches;
• quality validation;
• customer audits;
• regulatory approvals;
• technology transfer;
• commercial supply qualification.

The replacement cycle can take quarters or years.

That is why customer concentration matters even when the contract manufacturer owns excellent facilities.

Syngene also lost some lower-value discovery work

Management acknowledged attrition among some Research Services clients.

It specifically indicated that the company does not want to compete aggressively for commoditised discovery work purely on price.

The strategy is to reposition toward differentiated scientific services.

This may improve long-term quality.

It can depress revenue during the transition.

Forex created another ₹50 crore problem

This means Q1's 12% operating EBITDA margin should not automatically be treated as the permanent margin.

Management continues to guide for a full-year EBITDA margin in the mid-20s.

But the guidance now requires a major improvement during H2.

Syngene's reported EBITDA definitions need careful handling

Syngene reported operating EBITDA of approximately ₹91 crore.

Statutory EBITDA including other income and related items can be calculated at a somewhat higher level.

For evaluating core business performance, operating EBITDA is the more useful measure because it excludes certain non-operating effects.

Divi's reported EBITDA is not calculated under an identical company definition.

Divi's Q1 represented the opposite operating environment

The company benefited from:

• high-value Custom Synthesis shipments;
• strong plant utilisation;
• favourable product mix;
• backward integration;
• operating leverage.

Its margin reached approximately 40.8%.

Divi's model has fewer labour-intensive research layers

Divi's employs scientists and engineers too.

But its economics are more heavily tied to manufacturing campaigns.

It does not need Syngene-sized early-discovery teams to generate each rupee of commercial manufacturing revenue.

This helps explain why a favourable manufacturing mix can produce extraordinary percentage margins.

Divi's takes less early-stage discovery risk

Syngene can work on a molecule before anyone knows whether it will become a medicine.

The molecule may fail.

That research contract can still generate service revenue, but it may never become a manufacturing programme.

Divi's generally becomes economically important later when chemical process development and manufacturing scale are more relevant.

The customer may therefore be closer to commercialisation.

But Syngene's follow-the-molecule model has much greater upside per customer

A single drug programme can theoretically move through:

1. discovery;
2. development;
3. analytical testing;
4. clinical supply;
5. process development;
6. API manufacturing;
7. biologics manufacturing;
8. commercial supply.

If Syngene retains the molecule across multiple stages, revenue per customer can expand dramatically.

This is the strategic rationale for becoming an integrated CRDMO rather than a standalone research contractor.

The Bristol Myers Squibb partnership demonstrates this model

Syngene extended its long-running strategic collaboration with Bristol Myers Squibb through 2035.

The expanded collaboration spans:

• drug discovery;
• translational sciences;
• pharmaceutical development;
• manufacturing;
• clinical trials;
• data and technology services.

A relationship extending over decades is a powerful validation of scientific quality.

Long-term partnerships reduce some revenue volatility

Dedicated research-centre relationships can provide more visibility than transactional projects.

They also make Syngene deeply embedded inside client research workflows.

That creates switching costs.

But the Zoetis experience shows that concentration risk can still exist elsewhere in the portfolio.

Syngene is trying to become much more manufacturing-heavy

The company's next phase relies heavily on CDMO.

Management wants to increase utilisation across:

• Mangaluru small-molecule API manufacturing;
• Bengaluru biologics capacity;
• Unit 3 biologics manufacturing;
• Bayview biologics facility in the United States.

That is where the investment case begins to look more like Divi's.

Mangaluru is one of the largest latent earnings opportunities

Syngene's Mangaluru API facility historically operated at low utilisation.

Management says it has now secured several commercial and clinical molecule lock-ins.

Utilisation is expected to rise during FY27 and continue improving into FY28.

If successful, fixed manufacturing costs can be absorbed over a much larger revenue base.

This can create substantial operating leverage

A partially empty GMP plant still requires:

• quality staff;
• engineering;
• maintenance;
• utilities;
• depreciation;
• regulatory systems.

When capacity fills, many of those costs do not rise proportionately.

That means EBITDA can grow much faster than revenue.

Unit 3 expands Syngene's biologics capability

Syngene added a large multi-modal biologics manufacturing facility with approximately 20,000 litres of installed biologics drug-substance capacity and commercial-scale fill-finish capability.

Customers have already signed programmes and batches have been executed.

The challenge is increasing commercial utilisation.

Bayview makes Syngene an international manufacturer

Syngene acquired a biologics manufacturing facility in Baltimore, Maryland.

Combined with its Indian infrastructure, Syngene's total single-use bioreactor capacity reaches roughly 50,000 litres according to company materials.

This creates geographic flexibility for global customers.

It also meaningfully increases fixed costs before utilisation rises.

Bayview is therefore both an opportunity and a risk

If customers fill the facility:

• revenue can scale rapidly;
• Syngene gains a US manufacturing footprint;
• large pharma customers gain supply diversification;
• biologics becomes a larger earnings contributor.

If utilisation remains low, depreciation and operating costs can pressure returns.

Divi's does not carry the same discovery-to-biologics complexity

Divi's strategy is narrower.

It focuses on being extremely good at chemistry and manufacturing.

That reduces the number of technology platforms and scientific business models management needs to operate simultaneously.

This strategic simplicity is one reason its capital returns have historically remained strong.

Divi's has its own concentration risk

Custom Synthesis programmes can be large.

A small number of successful customer molecules can contribute meaningful revenue.

If a major drug loses market share or a manufacturing campaign shifts timing, quarterly revenue can change.

So Divi's is not immune to customer or product concentration.

The difference is that Q1 FY27 happened to show concentration working in its favour.

Custom Synthesis shipments are lumpy

Management has cautioned against extrapolating the Q1 60% Custom Synthesis mix indefinitely.

A large campaign can shift from one quarter to another.

That means Divi's 40.8% Q1 margin should not automatically be treated as a permanent steady-state number.

Syngene's FY27 guidance implies a major recovery

Management expects:

• single-digit revenue decline in rupee terms for FY27;
• a weak first half;
• stronger revenue momentum in H2;
• full-year EBITDA margins in the mid-20s.

After a 12% Q1 operating margin, achieving a mid-20s full-year result requires dramatically stronger later quarters.

Why management expects H2 improvement

The recovery thesis depends on several factors:

• Mangaluru utilisation increasing;
• cost-optimisation benefits;
• seasonally stronger Q4 revenue;
• new scientific contracts;
• CDMO programme ramp-ups;
• better utilisation of biologics assets.

Investors therefore have clear metrics to monitor.

FY27 is being treated as a rebuilding year

New Managing Director and CEO Siddharth Mittal took charge on July 1, 2026.

Kiran Mazumdar-Shaw moved into the Executive Chairperson role as the company reshaped leadership.

Management has described FY27 as a period of rebuilding rather than maximising growth.

That is a meaningful strategic reset.

Syngene is deliberately moving away from commoditised science

The company does not want to win discovery contracts solely by offering the lowest scientist cost.

It wants to differentiate through:

• advanced modalities;
• AI-enabled discovery;
• integrated development;
• biologics;
• clinical capabilities;
• specialised chemistry.

This can improve long-term margins if successful.

Syn.AI is part of that repositioning

Syngene has expanded its AI platform to support:

• virtual screening;
• molecule design;
• data-driven discovery;
• scientific productivity.

AI will not immediately replace the revenue lost in Q1.

Its strategic purpose is to improve the value of each scientist and reduce competition based purely on labour cost.

Divi's technology moat is less visible but equally important

Divi's competitive advantage lives in process chemistry.

A manufacturing process that:

• uses fewer steps;
• improves yield;
• reduces solvent usage;
• controls impurities;
• recycles valuable materials;
• operates reliably at large scale;

can create enormous economic value for a customer.

The two companies therefore monetise science differently

Balance sheets are strong for both

Divi's has effectively no financial debt under Bull Run's standardized field.

Syngene also carries very low leverage.

This matters because Syngene's current earnings weakness does not immediately create a balance-sheet crisis.

It has time to rebuild utilisation.

That is an important difference from a leveraged turnaround

A company with high debt and low utilisation can be forced to cut investment precisely when conditions are weakest.

Syngene's financial position gives management flexibility to:

• continue commercial investment;
• activate Bayview;
• build advanced capabilities;
• retain scientific talent;
• fund working capital.

ROCE nevertheless favours Divi's strongly

Syngene has invested heavily in facilities that are not yet producing adequate earnings.

That pushes ROCE down.

If Mangaluru, Unit 3 and Bayview ramp successfully, ROCE can improve materially without requiring proportionate new capex.

That is the core Syngene rerating argument

The company does not necessarily need another giant expansion programme.

It needs existing assets to fill.

Rising utilisation can improve:

• revenue;
• EBITDA margin;
• free cash flow;
• ROCE;
• earnings valuation.

Divi's challenge is different

Its current assets are already producing attractive earnings.

The company must prevent return dilution as new capacity enters service.

A debt-free balance sheet does not guarantee good capital allocation.

Even internally funded capex can destroy value if customers do not utilise it.

Valuation shows how differently the market views the two

Syngene trades at the lower P/E and a dramatically lower price-to-book multiple.

But that does not automatically make it cheaper.

Divi's currently earns far higher returns on capital.

Syngene's valuation depends on future recovery rather than current earnings quality.

Price-to-book makes the contrast particularly clear

Divi's trades at approximately 14.5 times book value.

Syngene trades near 3.3 times.

The market is willing to pay much more for every rupee of Divi's net assets because those assets currently generate far greater profit.

For Syngene to rerate, utilisation needs to close some of that return gap.

The one-year share-price divergence is enormous

Bull Run's latest standardized return shows Divi's up roughly 50% over one year.

Syngene is down approximately 37%.

This means expectations are now completely different.

Divi's is priced for continued excellence.

Syngene is priced for disappointment—but still trades at a high absolute P/E because trailing earnings remain relatively low.

What must Divi's prove?

• Custom Synthesis growth must continue after Q1's unusually favourable mix.
• New customer validation programmes need commercial conversion.
• Peptide investments should create meaningful revenue.
• 40%-plus Q1 margins must not collapse when mix normalises.
• New capex should preserve high returns on capital.
• Customer concentration needs continued management.
• An 80x-plus valuation must be supported by long-duration growth.

What must Syngene prove?

• H2 revenue must recover as management expects.
• Full-year operating EBITDA margin needs to move toward the mid-20s.
• Mangaluru utilisation should rise materially.
• Unit 3 biologics programmes need commercial ramp-up.
• Bayview should secure customers and begin productive utilisation.
• Research Services needs lower attrition and more differentiated work.
• Customer concentration should fall.
• ROCE needs to recover from the current single-digit level.

What could make Syngene outperform Divi's?

A successful utilisation-led turnaround.

Syngene's stock already reflects substantial disappointment.

If revenue rebounds while Mangaluru and biologics facilities absorb fixed costs, EBITDA can grow far faster than revenue.

At the same time, Divi's starts from a much richer price-to-book valuation and exceptionally high Q1 profitability.

That combination creates potential rerating asymmetry.

What could make Divi's continue outperforming Syngene?

Consistent Custom Synthesis conversion.

If Divi's new projects commercialise while Syngene struggles to replace major-client manufacturing revenue, the earnings-quality gap can remain very wide.

Which has the stronger current operating business?

Divi's Laboratories by a very large margin.

Its Q1 revenue grew 28%, EBITDA margin exceeded 40% and PAT reached ₹902 crore.

Which has the broader pharmaceutical-services platform?

Syngene International.

It can work with customers from discovery through clinical development and commercial small- and large-molecule manufacturing.

Which has the stronger biologics optionality?

Syngene.

It has built substantial biologics manufacturing capacity across India and the United States, including roughly 50,000 litres of combined single-use bioreactor capacity.

The issue today is utilisation rather than lack of capacity.

Which has the stronger capital efficiency?

Divi's Laboratories.

Bull Run's standardized ROCE is around 20.4% versus Syngene around 8.4%.

Which has the lower valuation?

Syngene on current P/E, sales and book-value multiples.

But its weaker valuation directly reflects lower earnings and execution risk.

It is a recovery valuation, not a like-for-like discount to Divi's current economics.

Which is better: Divi's Laboratories or Syngene International?

Divi's Laboratories currently has the stronger operating-quality profile. It is growing quickly, generating extraordinary margins, carrying essentially no debt and earning materially higher returns on capital.

Syngene currently offers the larger turnaround and asset-utilisation opportunity. It has a broad scientific platform, long-term relationships such as Bristol Myers Squibb through 2035 and significant underutilised small-molecule and biologics manufacturing infrastructure.

But the recovery is not yet visible in reported earnings.

Q1 revenue fell 16%, operating EBITDA fell 56% and PAT turned negative.

At September 2026 valuations, Divi's is the stronger company today. Syngene becomes the more interesting rerating case only if H2 revenue recovers, mid-20s full-year margins remain achievable and Mangaluru, Unit 3 and Bayview begin turning idle capacity into profitable commercial manufacturing revenue.

Frequently asked questions